EL-22
Preservation of lean muscle mass in patients on GLP-1 therapy for obesity
Key Facts
About NorthStrive Biotherapeutics
NorthStrive Biotherapeutics is targeting a significant gap in the rapidly expanding obesity therapeutics market by developing a muscle-preserving adjunct therapy. Its first-in-class asset, EL-22, is an oral engineered probiotic that activates the immune system to generate anti-myostatin antibodies, aiming to counteract the lean muscle loss associated with potent GLP-1 drugs. Having completed a Phase 1 trial in healthy volunteers, the company is positioning EL-22 for obesity and is led by a small management team with financial and scientific expertise. NorthStrive operates as a private, pre-revenue entity seeking to create a next-generation combination treatment paradigm for obesity.
View full company profile